Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results

被引：0
|
作者：
Swindells, S. [1 ]
Lutz, T. [2 ]
Van Zyl, L. [3 ]
Porteiro, N. [4 ]
Benn, P. [5 ]
Huang, J. [6 ]
Harrington, C. [7 ]
Hove, K. [8 ]
Ford, S. [9 ]
Talarico, C. [7 ]
Chounta, V. [5 ]
Crauwels, H. [10 ]
Van Solingen-Ristea, R. [10 ]
Vanveggel, S. [10 ]
Margolis, D. [7 ]
Smith, K. [7 ]
Vandermeulen, K. [10 ]
Spreen, W. [7 ]
机构：
[1] Univ Nebraska Med Ctr, Nebraska Med Ctr, Omaha, NE USA
[2] Infektiologikum, Frankfurt, Germany
[3] Syzygy Clin Res Serv, Pretoria, South Africa
[4] Fdn IDEAA, Buenos Aires, DF, Argentina
[5] ViiV Healthcare, Brentford, England
[6] GlaxoSmithKline, Mississauga, ON, Canada
[7] ViiV Healthcare, Res Triangle Pk, NC USA
[8] GlaxoSmithKline, London, England
[9] GlaxoSmithKline, Res Triangle Pk, NC USA
[10] Janssen Res & Dev, Beerse, Belgium
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P006
引用
收藏
页码：19 / 21
页数：3
相关论文
共 50 条
  • [41] Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong
    Chan, M. C. J.
    Chik, S. H. T.
    Lamb, S. S.
    Choi, Y. C. C.
    Lau, W. T. A.
    Leung, C. S. E.
    To, P. Y. L.
    Lau, P. L. D.
    Tsang, T. Y. O.
    [J]. HIV MEDICINE, 2023, 24 : 155 - 156
  • [42] A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
    Bares, Sara H.
    Scarsi, Kimberly K.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 22 - 31
  • [43] Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
    Margolis, David A.
    Gonzalez-Garcia, Juan
    Stellbrink, Hans-Juergen
    Eron, Joseph J.
    Yazdanpanah, Yazdan
    Podzamczer, Daniel
    Lutz, Thomas
    Angel, Jonathan B.
    Richmond, Gary J.
    Clotet, Bonaventura
    Gutierrez, Felix
    Sloan, Louis
    St Clair, Marty
    Murray, Miranda
    Ford, Susan L.
    Mrus, Joseph
    Patel, Parul
    Crauwels, Herta
    Griffith, Sandy K.
    Sutton, Kenneth C.
    Dorey, David
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    [J]. LANCET, 2017, 390 (10101): : 1499 - 1510
  • [44] The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study
    Trehan, Rekha
    Gutner, Cassidy
    Okoli, Chinyere
    Ghosn, Jade
    Vera, Francisco
    Florence, Eric
    Lutz, Thomas
    van der Valk, Marc
    Czarnogorski, Maggie
    [J]. HIV MEDICINE, 2023, 24 : 93 - 93
  • [45] Cabotegravir plus Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
    Sension, Michael G.
    Brunet, Laurence
    Hsu, Ricky K.
    Fusco, Jennifer S.
    Cochran, Quateka
    Uranaka, Christine
    Sridhar, Gayathri
    Vannappagari, Vani
    Van Wyk, Jean
    Mccurdy, Lewis
    Wohlfeiler, Michael B.
    Fusco, Gregory P.
    [J]. INFECTIOUS DISEASES AND THERAPY, 2023, 12 (12) : 2709 - 2724
  • [46] Safety and efficacy of cabotegravir plus rilpivirine long acting with and without oral lead-in: FLAIR week 124 results
    D'Amico, Ronald
    Orkin, Chloe
    Bernal Morell, Enrique
    Tan, Darrell H. S.
    Katner, Harold
    Singh, Yashna
    Stellbrink, Hans-Juergen
    Belonosova, Elena
    DeMoor, Rebecca
    Griffith, Sandy
    Thiagarajah, Shanker
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Ford, Susan L.
    Patel, Parul
    Cutrell, Amy
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Margolis, David A.
    St Clair, Marty
    Spreen, William R.
    Finkenzeller, Teresa
    [J]. INFECTION, 2021, 49 (SUPPL 1) : S7 - S7
  • [47] Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study
    Parker, Ben
    Ward, Tom
    Hayward, Olivia
    Jacob, Ian
    Arthurs, Erin
    Becker, Debbie
    Anderson, Sarah-Jane
    Chounta, Vasiliki
    Van de Velde, Nicolas
    [J]. PLOS ONE, 2021, 16 (02):
  • [48] Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study
    Garris, Cindy P.
    Czarnogorski, Maggie
    Dalessandro, Marybeth
    D'Amico, Ronald
    Nwafor, Toyin
    Williams, Will
    Merrill, Deanna
    Wang, YuanYuan
    Stassek, Larissa
    Wohlfeiler, Michael B.
    Sinclair, Gary, I
    Mena, Leandro A.
    Thedinger, Blair
    Flamm, Jason A.
    Benson, Paul
    Spreen, William R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 (09)
  • [49] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
    Jaeger, Hans
    Overton, Edgar
    Richmond, Gary
    Rizzardini, Giuliano
    Andrade-Villanueva, Jaime Federico
    Mngqibisa, Rosie
    Hermida, Antonio Ocampo
    Thalme, Anders
    Belonosova, Elena
    Ajana, Faiza
    Benn, Paul D.
    Wang, Yuanyuan
    Hudson, Krischan J.
    Espanol, Carlos Martin
    Ford, Susan L.
    Crauwels, Herta
    Margolis, David A.
    Talarico, Christine L.
    Smith, Kimberly Y.
    van Eygen, Veerle
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Spreen, William R.
    [J]. LANCET HIV, 2021, 8 (11): : E679 - E689
  • [50] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients
    Chounta, V.
    Snedecor, S.
    Wu, S.
    Van de Velde, N.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 23 - 24
12345